Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: Long-term follow-up of US intergroup study E2997

Blood

Volumn 118, Issue 13, 2011, Pages 3525-3527

  Smith, Mitchell R ^a   Neuberg, Donna ^b   Flinn, Ian W ^c   Grever, Michael R ^d   Lazarus, Hillard M ^e   Rowe, Jacob M ^f   Dewald, Gordon ^g   Bennett, John M ^h   Paietta, Elisabeth M ⁱ   Byrd, John C ^d   Hussein, Mohamad A ^j   Appelbaum, Frederick R ^k   Larson, Richard A ^l   Litzow, Mark R ^g   Tallman, Martin S ^m,n  

^a FOX CHASE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f RAMBAM MEDICAL CENTER   (Israel)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 5; CHROMOSOME 7; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOID NEOPLASIA; MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STEM CELL TRANSPLANTATION;

EID: 80053366228     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-342485     Document Type: Article

References (12)

1. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418-429.
2. Rowley JD, Golomb HM, Vardiman J. Nonrandom chromosomal abnormalities in acute non-lymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas. Blood. 1977; 50(5):759-770. (Pubitemid 8220708)
3. Bloomfield CD, Archer KJ, Mrazek K, et al. 11q23 Balanced chromosome aberrations in treatmentrelated myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33(4):362-378.
4. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17(8):2454-2460. (Pubitemid 29368245)
5. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. J Clin Oncol. 2002;20(18): 3878-3884.
6. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
7. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
8. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7): 793-798. (Pubitemid 350002879)
9. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010; 24(12):2056-2062.
10. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25(7):799-804. (Pubitemid 350010635)
11. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975- 980.
12. Ding W, Ferrajoli A. Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. Hematology Am Soc Hematol Educ Program. 2010;2010:90-92.